Medical technology company Cardiologs reported on Monday the receipt of US Food and Drug Administration (FDA) 510(k) clearance for its AI-powered cardiac diagnostics platform for paediatric cardiology based on an analysis of its improved deep learning algorithm.
Based on 20 million EKG recordings, the company used the new model to evaluate a global sample of 10,000 EKG readings from patients in various age groups. The updated algorithm improved average sensitivity over all major arrhythmias by 14% while reducing the number of false positives by 48%.
The company added that the new data shows improved deep learning algorithm performs equally across all age groups, enabling more patients to benefit from the company's cardiac diagnostics AI platform.
A policy statement published online recommended that all children be screened for the risk of sudden cardiac arrest (CA) or sudden cardiac death (SCD) at a minimum every three years. An increasing number of physicians are combining clinical expertise with AI-assisted analysis to improve detection for children and teens with abnormal heart rhythms, which can lead to earlier intervention and better outcomes.
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Medtronic receives FDA clearance for LigaSure RAS Maryland instrument on Hugo system
VaxThera partners with Codagenix for next generation yellow fever vaccine advancement
MaaT Pharma receives negative CHMP trend vote for MaaT013
FDA approves Scholar Rock's ISEMBYLD to treat spinal muscular atrophy
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
US FDA grants orphan drug designation for Lundbeck's asedebart
Renova Pharmaceuticals launches first three US generic products
FDA grants Priority Review to Genentech's Enspryng for MOGAD
CordenPharma increases aseptic fill-finish capacity
Biophytis expands BIO101 obesity study to assess weight regain